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OBJECTIVE: To evaluate the outcomes of acute myeloid leukemia patients who were older than 60 years of age at
the time of diagnosis following the implementation of a treatment algorithm based on age, performance status,
and cytogenetic results.
METHODS: We retrospectively compared the results of 31 elderly acute myeloid leukemia patients (median age of
74 years) who were treated according to the new algorithm.
RESULTS: Fifteen patients with a good performance status and no unfavorable karyotypes were treated with
either intensive cytotoxic chemotherapy (,70 years, nine cases) or adapted etoposide, 6-thioguanine and
idarubicine (.70 years, six cases); 16 cases with a poor performance status or unfavorable cytogenetics
received supportive care only. Six patients achieved a complete remission and two achieved a partial remission
after chemotherapy. There were three toxic deaths during induction, two in the adapted etoposide, 6-
thioguanine and idarubicine group and one in the intensive cytotoxic chemotherapy group. The overall
median survival time was 2.96 months, 1.3 months in the supportive care group, and 4.6 months in the
treatment group.
CONCLUSIONS: Our results illustrate the importance of treatment guidelines adapted to local resources in an
attempt to improve the survival of elderly acute myeloid leukemia patients in developing countries.
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INTRODUCTION
Acute myeloid leukemia (AML) comprises a heteroge-
neous group of clonal myeloid precursor cell disorders with
distinct clinical, morphologic, immunophenotypic, cytoge-
netic, and molecular features.
Age is one of the most important predictors of outcomes
in adult AML, and 20-30% of patients are older than 60
years of age at the time of diagnosis.1 The unfavorable
prognosis of elderly patients may be related to their poor
performance status, an increased incidence of high-risk
cytogenetic abnormalities, the common expression of multi-
drug resistance phenotypes, and the presence of previous
hematologic disorders.2 The treatment of elderly AML
patients is challenging, with poor response rates and high
mortality rates following intensive chemotherapy.3 A pre-
vious study from our group4 had similar findings, reporting
an adverse outcome in AML patients older than 60 with no
impact of intensive treatment on overall survival time.
The last two decades have brought few advances in the
outcomes and survival of elderly patients with AML des-
pite the introduction of new therapy modalities, including
granulocyte colony-stimulating factors, modulating drugs
of the multidrug resistance status and FLT3 inhibitors. Al-
though several centers recommend that the best treatment for
this group of patients is inclusion in new clinical trials, some
elderly patients may benefit from intensive chemotherapy
regimens. The correct selection of treatment remains funda-
mental to the management of this disease.1,2
Consistent with the above evidence and to improve our
results, we retrospectively evaluated the outcomes of elderly
AML patients treated at the Escola Paulista de Medicina,
Universidade Federal de Sa˜o Paulo after the implementation
of an adapted treatment algorithm based on age, perfor-
mance status, and cytogenetic results that benefited from the
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participation of a multidisciplinary team and the continuous
training of medical and nursing staff.
MATERIALS AND METHODS
Patients
The sample comprised 31 patients greater than 60 years of
age with a de novo AML diagnosis or with a previous
history of myelodysplastic syndrome. All the participants
had been diagnosed at the Escola Paulista de Medicina,
Universidade Federal de Sa˜o Paulo (UNIFESP) between
January 1, 2003 and July 31, 2008, and the sample
represented 26.27% (31/118) of all the adult AML cases
diagnosed in the institution during this period. The out-
comes of all the patients were followed until death. The
clinical features at presentation of all 31 patients are shown
in Table 1. This study was conducted according to the
requirements of the Institutional Review Board of UNIFESP.
Cytomorphologic, immunophenotypic, and
cytogenetic studies
Peripheral blood (PB) and bone marrow (BM) smears
collected using BM first-pull aspiration were stained with
May-Gru¨nwald-Giemsa (MGG), and cell morphology was
analyzed using conventional bright-field microscopy.
Immunophenotypic studies were performed in BM sam-
ples using a four-color combination of monoclonal antibodies
(MAbs). Immunofluorescence staining was performed using
a standardized direct stain-and-then-lyse-and-wash techni-
que combined with fixation and permeabilization for the
detection of intracellular antigens. Immediately after staining,
samples were acquired using a FACSCalibur flow cytometer
(Becton-Dickinson, San Jose, CA, USA) using the CellQuest
software program (Becton-Dickinson, San Jose, CA, USA).
For cytogenetic analysis, 5 ml of each BM samples
was collected in a syringe containing sodium heparin.
Karyotyping was performed using standard techniques,
and the results were reported according to the International
System for Human Cytogenetic Nomenclature guidelines.5
At least 20 G-banded metaphases were analyzed. A clone
was defined either as two BM cells showing the same gain
of chromosomal material or the same structural aberra-
tion or as at least three BM cells showing loss of the
same chromosome. A complex aberrant karyotype was
defined as three or more independent cytogenetic abnorm-
alities in at least two BM cells. Cytogenetic risk was de-
fined according to the National Comprehensive Cancer
Network guidelines.6
AML was diagnosed and classified according to the
World Health Organization (WHO) criteria, which define
AML as the presence of at least 20% of blasts in a BM sample
or the presence of a recurrent cytogenetic abnormality.7
Treatment protocols
Patients were treated according to their age, Eastern
Cooperative Oncology Group (ECOG) performance status,
comorbidities, and cytogenetic risks and were divided into
two groups: treatment and supportive care.
In the treatment group, patients younger than 70 years of
age with a good performance status (ECOG index ,II) and
no unfavorable karyotypes were treated with intensive
cytotoxic induction chemotherapy comprising intravenous
(IV) cytarabine (200 mg/m2 per day for seven days) and IV
daunorubicin (45 mg/m2 per day on days 1-3). Patients who
were older than 70 years of age but had a good performance
status and no unfavorable cytogenetics were treated with an
alternative chemotherapy regimen adapted from the Finnish
Leukemia Group (ETI protocol),8-10 which comprised IV
Table 1 - Patient characteristics at the time of diagnosis in the two groups.
Supportive care (n= 16) Treatment (n = 15)
Adapted ETI (n = 6) Intensive treatment (n= 9)
Median age (range) 79 (60-89) 77 (68-80) 68 (60-75)
Gender (male/female) 6/10 3/3 6/3
ECOG performance status
0 1 1 1
I 8 5 8
II 3 0 0
III 4 0 0
IV 0 0 0
Karyotype
Low risk 0 2 1
t(8;21) 0 1 1
inv(16) 0 1 0
Standard risk 8 1 3
Normal 3 1 2
del(20 q) 0 0 1
+8 3 0 0
t(8;16) 2 0 0
Unfavorable risk 4 1 1
complex karyotype 1 1 0
del(7) 1 0 1
t(1;3) 1 0 0
del(11 q)(23) 1 0 0
Unknown 4 2 4
Hb (g/dL) 8.53 6.5 6.5
WBC (6109/L) 56.5 21.6 20.1
Platelets (6109/L) 58 38.7 30
Bone marrow blast cells (%) 57.5 (21-97) 56.5 (20-92) 46 (20-79)
Splenomegaly 3/16 1/6 1/9
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etoposide (80 mg/m2 twice daily on days 1-5); IV thiogua-
nine (100 mg/m2 twice daily on days 1-5) and IV mitoxan-
trone (12 mg/m2 once daily on days 1-3). The original ETI
protocol contained idarubicine, which was replaced by
mitoxantrone in our study because of the unavailability of
this chemotherapeutic agent in our hospital and the similar
pharmacodynamic features of both drugs. The response
assessment criteria were defined according to the guidelines
reported by Cheson et al.11
Complete remission was defined by the following criteria:
the presence of ,5% blast cells; the absence of blasts with
Auer rods; the absence of extramedullary disease; an
absolute neutrophil count .1.06109/l and a platelet count
.1006109/l. Partial remission was defined as a decrease in
BM blast percentage to 5-25% and a decrease in the
pretreatment BM blast percentage by at least 50%. The
overall survival time was the time measured from the date
of leukemia diagnosis to the date of death from any cause.
After the achievement of complete remission, consolidation
therapy was identical to induction therapy in both
treatment schedules. Granulocyte colony-stimulating factor
was administrated to all patients who presented with a
neutrophil count ,0.56109 cells/l after chemotherapy
administration.
Patients with a poor performance status and those with
unfavorable cytogenetics were treated with supportive care,
regardless of age. Monotherapy with hydroxycarbamide
500-1500 mg/day was initiated when the white blood cell
count was .206109/l, and blood cell transfusions and
antibiotic therapy were administrated when necessary.
Statistical analyses
Analyses were performed on an intention-to-treat basis.
The response rates of the different patient groups were
compared using the chi-squared (x2) test of proportions.
Overall survival time was estimated with the Kaplan-Meier
method and compared using the log-rank test. A p-value
less than 0.05 was considered statistically significant.
Statistical analyses were performed using SPSS 12.0 soft-
ware (Chicago, USA).
RESULTS
Patient characteristics
The median age was 74 years (range 60 to 89 years), and
the male:female ratio was 151. Fifteen patients received
treatment [nine with intensive chemotherapy and six with
adapted etoposide, 6-thioguanine and idarubicine (ETI)],
and 16 received supportive care. The median ages in the
treatment and supportive care groups were 68 and 79 years
old, respectively. According to the WHO classification
criteria, the cases were subdivided into the following
groups: three cases of AML with recurrent translocations
(two with t(8;21) and one with inv(16)); 11 cases of AML
with myelodysplasia-related changes; one case of therapy-
related AML and 16 cases of AML not otherwise specified
(one case of AML with minimal difference, four of AML
without maturation, four of AML with maturation, two of
acute myelomonocytic leukemia, three of acute monoblastic
leukemia and two of erythroleukemia). At diagnosis, the
patients’ hemoglobin levels ranged from 2.9 to 15.5 g/dl
(median 7.5 g/dl), and the white blood cell counts ranged
from 1.1 to 1286109 cells/l (median 39.56109 cells/l). The
ECOG performance status, the BM blast cell percentage, and
the presence of splenomegaly are listed in Table 1.
Cytogenetic studies were performed in 29 patients, and 21
(72.4%) presented the following karyotype results: three had
low-risk abnormalities (14.3%), twelve had intermediate-
risk abnormalities (57.1%) and six had high-risk abnormal-
ities (28.6%).
Response and survival time
Table 2 shows the overall responses of the AML patients
by patient group. In the intention-to-treat analysis used, the
overall response (complete remission + partial remission) of
the patients who received treatment (8 of 15 patients, 53.3%)
was superior to the response of the patients in the
supportive care group (0 of 16 patients) (p,0.05). Of the
six patients who achieved complete remission following
induction, five received intensive therapy, and one received
adapted ETI. In all, two patients achieved a partial response,
and both were in the ETI group. One patient presented with
treatment failure after ETI, and three patients presented
with treatment failure after intensive chemotherapy. Three
toxic deaths occurred during induction: two in the adapted
ETI group and one in the intensive chemotherapy group. All
the toxic deaths were due to severe infection.
The overall median survival time was 2.96 months (range
0.07 to 9.5): 1.3 months in the supportive care group and 4.6
months in the treatment group. The p-value produced by
the log-rank test was p= 0.001 for the comparison between
the two groups. The treatment comparisons in terms of
overall survival time are shown in Figure 1.
Patients older than 70 years of age exhibited a median
survival time of 2.8 months, and no significant difference
was observed between them and the patients less than 70
years old (3.4 months, p= 0.86).
Time of hospitalization
The median duration of hospitalization was 1.6 months
overall (range 0.07 to 5.2) and 0.56 and 2.8 months in the
supportive care and treatment groups, respectively. The rate
of hospitalization during the follow-up period did not vary
significantly by patient group (75.7% for the supportive care
group and 77.6% for the treatment group).
Table 2 - Response rates and overall survival times by patient group.
Supportive care
(n = 16) Adapted ETI (n = 6)
Intensive treatment
(n = 9)
ETI + intensive
treatment (n= 15)
Response rate
Complete remission 0 1 5 6
Partial remission 0 2 0 2
Resistant disease 16 1 3 4
Death during induction 0 2 1 3
Overall survival time in months (range) 1.3 (0.07-9.2) 4.4 (1.05-7.25) 4.6 (0.92-9.5) 4.6 (0.92-9.5)
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DISCUSSION
The results confirm the unfavorable prognosis of AML
patients older than 60 years of age. The overall survival time
was 2.9 months, and patients selected to receive intensive
cytotoxic treatment or an alternative treatment (adapted ETI)
experienced significant increases in overall survival time
compared with patients who received supportive care only.
However, the survival times described in this study are
inferior to those reported in developed countries.1,2 This
phenomenon may be attributed to both socioeconomic
differences and characteristics of the Brazilian national public
health system. Brazil was one of the first countries in Latin
America to make universal access to free health care a
constitutional right, and the available services range from
primary care to highly technologically complex treatments.12
Nevertheless, this system has not been fully implemented,
and patients wait a long time for access to specialized
services.13 This delay is particularly experienced by patients
waiting to access the limited number of specialized hematol-
ogy centers. The optimal management of AML and other
hematological malignancies14 necessitates a prompt diagno-
sis and the initiation of treatment without delay.
A number of new chemotherapy agents are under
investigation in older patients with AML, such as DNA
methyltransferase inhibitors (e.g., decitabine) and the
purine nucleoside analog clofarabine. However, such drugs
are not available via the public health services of developing
countries, and alternative treatments are necessary for the
management of elderly patients not suitable for intensive
chemotherapy.
The Finnish Leukemia Group has proposed an alternative
oral treatment composed of etoposide, 6-thioguanine and
idarubicine that displays good response rates and an
acceptable toxicity profile in advanced age AML patients.8-10
The adapted ETI evaluated herein was associated with a
significant increase in AML survival time and may be an
alternative approach for the treatment of older patients who
cannot participate in clinical trials.
The prevalence and survival times of AML in advanced
age have not been adequately studied in Latin American
countries. Beyrı´es et al. reported that Cuban AML patients
older than 60 years of age experienced an overall median
survival time of less than two months, and those selected to
receive high-dose chemotherapy presented high rates of
resistance and mortality.15 A previous study conducted by
our group showed that 33% of all AML cases occurred in
patients who were older than 60 years of age, and the
overall survival time was two months.4 Moreover, no
difference in overall survival time was noted between
elderly AML patients who received intensive cytotoxic
chemotherapy and those who received supportive care,
suggesting that this group of patients should receive only
palliative treatment. Five years later, our results indicate a
historical improvement in the treatment of elderly patients
with AML. This change can be attributed to a paradigm shift
in the selection of therapeutic modalities coupled with
improved medical and nursing training and better medical
support. Despite the improvement in the overall survival of
these patients, there was no difference in the hospitalization
rate between the patient groups.
The impact of treatment guidelines adapted to local
resources is exemplified by the initiative of the International
Consortium on Acute Promyelocytic Leukemia (APL)16 to
improve the response and cure rates and reduce the mortality
associated with APL treatment in developing countries.
Figure 1 - Overall survival time of elderly AML patients according to patient group, 2003-2008.
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The low number of patients enrolled in our study could
be interpreted as a limitation, and a larger number of AML
cases are currently being followed by our hospital to
confirm our findings.
In conclusion, as part of the ongoing search to enhance the
quality of health care and with all limitations of a single
institution in the Brazilian public health system, we
implemented a medical assistance approach that showed
benefits for the management of AML patients. The
treatment of AML in advanced age is challenging, and
some patients may benefit from treatment with intensive or
alternative chemotherapy that is appropriate for their age,
performance status, and cytogenetics. We believe that
outcomes in elderly AML patients can be improved by
better and faster access to specialized health services,
consistent training of medical and nursing staff in all
spheres of care and the development of therapeutic
algorithms and planned solutions that are directed at and
customized for different regional realities.
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